NetworkNewsBreaks – AREV Life Sciences Global Co
Post# of 16
(Total Views: 169)
Posted On: 03/11/2022 3:14:23 PM
NetworkNewsBreaks – AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Announces Collaboration Agreement with RCFFN, University of Manitoba
AREV Life Sciences (CSE: AREV) (OTC: AREVF) has announced its engagement of the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals (“RCFFN”) to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN,” AREV’s next-generation Ready to Use Therapeutic Food (“RUTF”). According to the announcement, AREV, through its U.S. subsidiary in Rochester, New York, is developing the aflatoxin-free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives from several academic research institutions, including the Institute for Human Virology (“IHV”), The Linus Pauling Institute (“LPI”) at Oregon State University (“OSU”) and the RCFFN at the University of Manitoba. “AREV’s development of SUSATAINN is now being enhanced by this collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba,” said Dr. Roscoe Moore, chairman of the scientific advisory board for AREV Life Sciences, and board member of Global Virus Network. “Our product development and research from Linus Pauling Institute has provided the initial data to be applied with the scientists at the Richardson Centre for Functional Foods and Nutraceuticals in order to accelerate the introduction of SUSTAINN into public health commodity procurement program utilization to combat global famine and serious and acute malnutrition during the intersection of COVID-19 and other pandemic infections that are driving a global decline of life expectancy and childhood mortality.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AREV Life Sciences (CSE: AREV) (OTC: AREVF) has announced its engagement of the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals (“RCFFN”) to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN,” AREV’s next-generation Ready to Use Therapeutic Food (“RUTF”). According to the announcement, AREV, through its U.S. subsidiary in Rochester, New York, is developing the aflatoxin-free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives from several academic research institutions, including the Institute for Human Virology (“IHV”), The Linus Pauling Institute (“LPI”) at Oregon State University (“OSU”) and the RCFFN at the University of Manitoba. “AREV’s development of SUSATAINN is now being enhanced by this collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba,” said Dr. Roscoe Moore, chairman of the scientific advisory board for AREV Life Sciences, and board member of Global Virus Network. “Our product development and research from Linus Pauling Institute has provided the initial data to be applied with the scientists at the Richardson Centre for Functional Foods and Nutraceuticals in order to accelerate the introduction of SUSTAINN into public health commodity procurement program utilization to combat global famine and serious and acute malnutrition during the intersection of COVID-19 and other pandemic infections that are driving a global decline of life expectancy and childhood mortality.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)AREV NanoTec Brands Inc. (AREVF) Stock Research Links
Scroll down for more posts ▼